The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 shares worth approximately $2.8 million on April 10-13, 2026, reducing his direct holdings by 4.9%. While the sale is not necessarily alarming given his substantial remaining stake of nearly 3 million shares, the company remains a high-risk investment. MoonLake's stock has fallen 47.47% over the past year following disappointing clinical trial results for its lead therapy Sonelokimab, though the FDA granted it fast-track designation. The pre-revenue biotech company burns approximately $65 million quarterly but has $394 million in cash reserves.

04/18/2026, 10:17 AM • The Motley Fool

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

BVF Partners L.P., a biotech-focused hedge fund, sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million on April 2, 2026, reducing its direct stake by 78.3%. The sale appears to be portfolio rebalancing rather than a full exit, as BVF retains 15.9 million shares. MoonLake, a clinical-stage immunotherapy company developing sonelokimab for inflammatory diseases, has experienced a 53.35% stock decline over the past year despite recent positive clinical trial results.

04/07/2026, 2:07 PM • The Motley Fool

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics announced Week 40 results from its Phase 3 VELA clinical trials of sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The drug demonstrated continued clinical improvement with 62% of patients achieving HiSCR75 response and up to 32% achieving HiSCR100. Patients also showed substantial improvements in quality of life measures, with up to 25% achieving inflammatory remission. No new safety signals were detected. The company expects to present detailed results at the 2026 AAD Annual Meeting and has upcoming milestones including 52-week data readout and BLA submission in H2 2026.

03/28/2026, 3:00 PM • GlobeNewswire

MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile

MoonLake Immunotherapeutics has rallied over 30% in the past month following FDA regulatory victories. The company received Fast Track designation for Sonelokimab in treating Palmoplantar Pustulosis and FDA confirmation that existing data is sufficient for approval in Hidradenitis Suppurativa. With $380.5 million in cash runway extending into late 2027, the company has de-risked its investment profile. An upcoming Investor Day on February 23, 2026 will showcase Phase 2 trial data, with potential short squeeze dynamics given 12.7% short interest.

02/04/2026, 11:29 AM • Investing

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

MoonLake Immunotherapeutics announced that the FDA has granted Fast Track designation for sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP), based on positive Phase 2 LEDA trial results. The designation enables more frequent FDA interactions and potential expedited review pathways. The company will discuss this milestone and provide updates on multiple clinical programs at an Investor Day on February 23, 2026, including Phase 2 S-OLARIS data in axial spondyloarthritis and progress toward a BLA submission for hidradenitis suppurativa in H2 2026.

02/02/2026, 8:00 AM • GlobeNewswire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.

12/15/2025, 8:55 AM • Benzinga

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics, alleging the company made false claims about its drug candidate sonelokimab and misled investors about its treatment superiority, resulting in a 90% stock value loss.

12/15/2025, 3:25 AM • Benzinga

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging securities fraud related to misrepresentations about their drug candidate sonelokimab, which led to significant stock value loss.

12/14/2025, 12:00 PM • GlobeNewswire

MLTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX

Rosen Law Firm is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics, alleging false and misleading statements about their Nanobody technology and its clinical benefits during the period of March 10, 2024 to September 29, 2025.

12/14/2025, 9:00 AM • GlobeNewswire

MLTX 2-DAY DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

Hagens Berman is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics after its stock plummeted 90% following disappointing Phase 3 trial results for its lead drug sonelokimab, alleging the company made misleading claims about its Nanobody technology's clinical efficacy.

12/13/2025, 1:07 PM • GlobeNewswire

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet 89.9%.

12/13/2025, 9:21 AM • GlobeNewswire

MLTX FRAUD UPDATE: Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15

MoonLake Immunotherapeutics faces a securities fraud class action lawsuit after reporting disappointing Phase 3 VELA trial results for its investigational drug sonelokimab, causing its stock price to drop nearly 90%.

12/13/2025, 7:18 AM • GlobeNewswire

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Law firm alerts investors about a potential securities fraud class action lawsuit against MoonLake Immunotherapeutics after disappointing Phase 3 drug trial results caused significant stock price decline.

12/12/2025, 8:51 PM • Benzinga

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)

Law firm Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines for class action lawsuits against MoonLake Immunotherapeutics, DexCom, and Synopsys, alleging false statements and material fact omissions during specific time periods.

12/12/2025, 8:00 AM • GlobeNewswire

DEADLINE ALERT for MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts investors about potential securities fraud class action lawsuits for MoonLake Immunotherapeutics, Baxter International, and James Hardie Industries, with upcoming lead plaintiff filing deadlines in December 2025.

12/11/2025, 8:40 PM • GlobeNewswire